Collegium Pharmaceutical (COLL) Stock Forecast, Price & News

Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

Is Collegium Pharmaceutical a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Collegium Pharmaceutical stock.
View analyst ratings for Collegium Pharmaceutical or view top-rated stocks.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Collegium Pharmaceutical.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.90 by $0.46. The specialty pharmaceutical company earned $83.80 million during the quarter, compared to the consensus estimate of $78.67 million. Collegium Pharmaceutical had a trailing twelve-month return on equity of 3.26% and a net margin of 15.68%. The company's quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.41 EPS.
View Collegium Pharmaceutical's earnings history.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical issued an update on its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $450.00 million-$465.00 million, compared to the consensus revenue estimate of $448.72 million.

What price target have analysts set for COLL?

4 Wall Street analysts have issued 1 year target prices for Collegium Pharmaceutical's stock. Their forecasts range from $26.00 to $42.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $33.25 in the next year. This suggests a possible upside of 108.6% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical or view top-rated stocks among Wall Street analysts.

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the following people:

• Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph., Co-Founder & Chairman (Age 58, Pay $110k) (LinkedIn Profile)
• Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 51, Pay $1.1M)
• Ms. Colleen Tupper, Exec. VP & CFO (Age 46, Pay $631.24k)
• Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. (Age 38, Pay $620.1k) (LinkedIn Profile)
• Mr. Scott Dreyer, Exec. VP & Chief Commercial Officer (Age 49, Pay $591k) (LinkedIn Profile)
• Dr. Richard Malamut, Exec. VP & Chief Medical Officer (Age 62, Pay $612.2k)
• Ms. Alex Dasalla, Head of Investor Relations
• Mr. Bart J. Dunn, Exec. VP of Strategy & Corp. Devel.
• Ms. Marlo Manning, Head of HR
• Mr. Scott Sudduth, Head of Technical Operations

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical CEO Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among Collegium Pharmaceutical's employees.

Who are some of Collegium Pharmaceutical's key competitors?

Some companies that are related to Collegium Pharmaceutical include Sage Therapeutics (SAGE), Amphastar Pharmaceuticals (AMPH), Schrödinger (SDGR), Turning Point Therapeutics (TPTX), Emergent BioSolutions (EBS), Ironwood Pharmaceuticals (IRWD), Global Blood Therapeutics (GBT), Aurinia Pharmaceuticals (AUPH), ChemoCentryx (CCXI), HUTCHMED (HCM), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN) and Xenon Pharmaceuticals (XENE).
View all of COLL's competitors.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), (CGC), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.85%), Vanguard Group Inc. (6.80%), Principal Financial Group Inc. (4.18%), State Street Corp (3.86%), Renaissance Technologies LLC (3.74%) and Invesco Ltd. (2.98%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends for Collegium Pharmaceutical.

Which major investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, South Dakota Investment Council, Qube Research & Technologies Ltd, Royce & Associates LP, Summit Global Investments, Peregrine Capital Management LLC, and Factorial Partners LLC.
View insider buying and selling activity for Collegium Pharmaceutical or view top insider-selling stocks.

Which major investors are buying Collegium Pharmaceutical stock?

COLL stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, State Street Corp, Principal Financial Group Inc., Russell Investments Group Ltd., Los Angeles Capital Management LLC, BlackRock Inc., Pacer Advisors Inc., and Exchange Traded Concepts LLC.
View insider buying and selling activity for Collegium Pharmaceutical or or view top insider-buying stocks.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $15.94.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical has a market capitalization of $540.73 million and generates $276.87 million in revenue each year. The specialty pharmaceutical company earns $71.52 million in net income (profit) each year or $0.889990 on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

Collegium Pharmaceutical employs 152 workers across the globe.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at [email protected].